Navigation Links
ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
Date:4/17/2009

SAN DIEGO, April 17 /PRNewswire/ -- ChemDiv, a global chemistry-driven contract research organization, announced today that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe. Prudentas will continue to operate separately under the business name Prudentas LLC, a ChemDiv Group company.

Prior to the acquisition ChemDiv had worked with Prudentas, who established itself as an experienced, professional, and reliable CRO collaborator, in response to a growing interest of ChemDiv's pharmaceutical and biotech partners in conducting quality and expeditious clinical trials.

ChemDiv sees great potential in this acquisition by adding value to ChemDiv's Discovery outSource(TM) services offered to pharmaceutical and biotech companies worldwide.

Nikolay Savchuk, President and CEO of ChemDiv, Inc. commented: "Our decision to make this investment capitalizes on the growing trend of conducting clinical trials in Eastern Europe; based on the availability of naive patient populations, rapid and efficient trial recruitment and high data quality across a broad range of therapeutic indications including CNS, cardiovascular and metabolic disorders, oncology, inflammation, and infectious disease; areas already covered by our Discovery outSource(TM) service. This acquisition is synergistic to the continued development of our Chemical Diversity Research Institute subsidiary, and our other discovery services holdings such as Drugs Technology Ltd., which provides GLP/GMP formulation and CMC services. We believe Prudentas will help us bring unique levels of clinical development productivity to pharma and biotech partners through risk mitigation, cost- and time savings. This acquisition further strengthens and expands our global presence specifically in the Eastern European and Eurasian markets and responds to growing customer demand for comprehensive R&D outsourcing."

Dmitry Prudnikov, CEO of PRUDENTAS LLC, noted: "Since its creation Prudentas focused on early phases of clinical trials, and integration with ChemDiv will allow our clients to get unique opportunity in studying their compounds with us from pre-clinical testing to Proof-of-Concept trials. Our such "solid program" integrated approach to increasing external R&D programs value will certainly save time and money for our clients, and creates an attractive proposition for many of our existing and potential sponsors.

About ChemDiv

ChemDiv, Inc. (ChemDiv) is a global contract research discovery and development organization headquartered in San Diego, CA, USA with subsidiaries in Russia, business and logistics operations around the world. ChemDiv provides external integrated discovery and development solutions to pharma and biotech partners based on the Discovery outSource(TM) platform. It covers the complete range of disciplines needed to bring a CNS, oncology, inflammation, metabolic and infectious disease projects from identification of a biological target to clinical drug and drug development candidates. Visit www.chemdiv.com for more information.

About Prudentas

PRUDENTAS is a Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team. PRUDENTAS appeared in response to the growing interest of pharmaceutical and biotech companies in conducting clinical trials in Russia and Ukraine, which resulted in the increasing number of clinical trials brought here within the last years.

PRUDENTAS aspires to mirror the highest international standards of service and quality, strictly adhering to the legal regulations of countries where it operates and that of the home countries of its clients.

PRUDENTAS is a client-focused, performance-driven, and result-oriented team offering to pharmaceutical and biotech companies a cost-effective solution for Phase I -- IV clinical trials conduct in Russia and Ukraine with fast recruitment and high quality. For more information please visit www.prudentas.com.

About ChemRar

The ChemRar High-Tech Center is a unique pharma and biotechnology complex in founded Moscow, Russia by highly innovative life science R&D organizations. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. ChemRar's mission is to bring novel therapies for unmet needs in treating CNS, oncology, cardiovascular, metabolic and infection disease using novel post genomic technology platforms.


'/>"/>
SOURCE ChemDiv, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ChemDiv and Avineuro Extend Collaboration on Alzheimers Disease and Schizophrenia
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. ChemDiv and Achaogen Enter Into a Discovery Collaboration
4. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
5. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
6. GSI Group Inc. to Restate Financial Results for 2006
7. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
8. Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That Positive Cash Flow Is Possible in 09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
9. Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
10. Disabled and other vulnerable groups more susceptible to terrorism fears
11. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... December 31, 2015. --> --> ... net loss of $29.3 million, or $0.34 loss per share, compared ... share for the same period in 2014. For the year ended ... million, or $1.05 loss per share, as compared to a net ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:2/11/2016)... 2016  Vigilant Solutions announces today that its license plate ... by Lee,s Summit Police Department to ... arrest of a homicide suspect. Kansas City ... 65 square miles and is home to roughly 100,000 residents. ... single mobile license plate reader system and also leverages Vigilant,s ...
(Date:2/8/2016)... PRAGUE, Czech Republic , February 8, 2016 ... first EU-regulated global payment platform which presents innovation ... Voice Biometrics Authentication feature called VoiceKey. --> ... payment platform which presents innovation for clients, comfort ... feature called VoiceKey. --> Worldcore ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
Breaking Biology News(10 mins):